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Abstract
Allogeneic hematopoietic cell transplantation (HCT) is a treatment for various hematologic
diseases where efficacy of treatment is in part based on the graft versus tumour (GVT) activ-
ity of cells in the transplant. The cytoprotective enzyme heme oxygenase-1 (HO-1) is a rate-
limiting enzyme in heme degradation and it has been shown to exert anti-inflammatory func-
tions. In humans a (GT)n repeat polymorphism regulates the expression of HO-1. We con-
ducted fragment length analyses of the (GT)n repeat in the promotor region of the gene for
HO-1 in DNA from donors and recipients receiving allogeneic myeloablative- (MA) (n = 110)
or nonmyeloablative- (NMA-) (n = 250) HCT. Subsequently, we compared the length of the
(GT)n repeat with clinical outcome after HCT. We demonstrated that transplants from a HO-
1high donor after MA-conditioning (n = 13) is associated with higher relapse incidence at 3
years (p = 0.01, n = 110). In the NMA-conditioning setting transplantation of HO-1low donor
cells into HO-1low recipients correlated significantly with decreased relapse related mortality
(RRM) and longer progression free survival (PFS) (p = 0.03 and p = 0.008, respectively).
Overall, our findings suggest that HO-1 may play a role for the induction of GVT effect after
allogeneic HCT.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is an effective therapeutic option for
patients with various hematologic malignancies. Current challenges include reducing graft-
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versus-host disease (GVHD) while maintaining or augmenting the beneficial graft-versus-
tumour effect (GVT) [1]. Donor-derived type 1 T cells are known to be major players in GVT
and GVHD which involve killing of tumour cells as well as healthy cells and tissues, respec-
tively [1].
Heme oxygenase-1 (HO-1) is a rate limiting stress-responsive enzyme that degrades heme
into biliverdin, carbon monoxide and free iron [2]. It is induced by various oxidative agents
and exerts anti-inflammatory and cytoprotective effects hereby controlling inflammation and
inducing tolerance [3]. To this end, dendritic cells expressing HO-1 retain an immature
phenotype which promote differentiation of Tregs and inhibit effector T-cell responses [3].
Indeed, it could be speculated that the immune suppressive functions of HO-1 may influence
the immune mechanisms underlying the effects of allogeneic HCT. It has been demonstrated,
that a (GT)n dinucleotide repeat in the promoter region of the HO-1 encoding gene,HMOX1,
regulates the expression of HO-1 [4]. Shorter (GT)n repeats leads to increased transcriptional
activity and, thus, a higher expression of HO-1 upon oxidative stimuli [5].
The purpose of our study was to examine a possible association of the association between
the HO-1 (GT)n repeat polymorphism and clinical outcomes after both myeloablative (MA) or
nonmyeloablative (NMA) allogeneic HCT.
Methods
Patients and controls
The study population consisted of patients with malignant hematologic diseases that received
related or unrelated donor HCT after MA conditioning (n = 110) or NMA conditioning
(n = 250) (Table 1) between March 2000 and July 2007 at the bone marrow transplantation
unit at Rigshospitalet, Copenhagen, Denmark. Transplant regimens and supportive care have
been described elsewhere [6]. Acute GVHD and chronic GVHD were graded according to
standard criteria [7]. Samples from related and unrelated donors were obtained from leuka-
pheresis products whereas peripheral blood samples were obtained from healthy donors. DNA
was extracted as previously reported using the Promega Maxwell 16 blood DNA kit (Promega
Corporation, Madison, WI) [8]. Written informed consent was obtained from all recipients
and donors and the study and consent procedure was approved by the Scientific Ethics Com-
mittee for The Capital Region of Denmark. Our healthy cohort included DNA from 74 indi-
viduals from the Danish general population [9].
Fragment length analyses of the (GT)n repeat in the promoter region of
the HMOX1 gene
To determine the number of (GT)n repeats in the promoter region, polymerase chain reac-
tion (PCR) was carried out to amplify the (GT)n repeat region using a forward primer labeled
with a dye (FAM). Forward primer: 5’-FAM-AGAGCCTGCAGCTTCTCAG-3’, reverse
primer: 5-AAACAAAGTCTGGCCATAGGAC-3’ (TAG Copenhagen, Denmark). Amplifica-
tions were carried out in a total volume of 15 μl containing 1x PCR buffer (50 mM KCl, 20
mM Tris pH 8.4, 2.0 mM MgCl2, 0.2 mM cresol red, 12% sucrose, 0.005% (wt/v) BSA (Boeh-
ringer-Mannheim, Germany), 5 pmol of each primer, 40 mM dNTPs (Pharmacia LKB, Swe-
den) and 1.25 U of AmpliTaq polymerase (Perkin Elmer Cetus Corporation, Emeryville, CA,
USA). To minimize non-specific amplification, we carried out “touch down” PCR where
annealing temperature is higher than target optimum in early PCR cycles followed by a
decrease by 0.5˚C in every following cycle. Genotyping was performed by analyses of PCR
HO-1 (GT)n Polymorphism in Allogeneic HCT
PLOS ONE | DOI:10.1371/journal.pone.0168210 December 20, 2016 2 / 8
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Table 1. Patient demographics.
PATIENTS Myeloablative cohort(n = 110) Nonmyeloablative cohort(n = 250)
Patient age, median years (range) 40 (16–57) 56 (19–74)
Sex of patient
M 66 (60%) 157 (63%)
F 44 (40%) 93 (37%)
Disease
AML 44 (40%) 77 (31%)
ALL 32 (29%) 1 (0%)
MDS (de novo) 16 (15%) 40 (16%
MDS (therapy related) 0 (0%) 8 (3%
CML 15 (14%) 5 (2%)
NHL 3 (3% 46 (18%
MM 0 (0%) 12 (5%)
HD 0 (0%) 15 (6%
CLL 0 (0%) 46 (18%)
Conditioning regimen
TBI (12 GY) + Cyclophosphamide 61 (56%) -
TBI (12 GY) + Etoposide 39 (35% -
Cyclophosphamide (+/- Busulfan) 9 (8%) -
Fludarabine, Thiotepa and Melphalan 1 (1%) -
TBI (2 GY) + Fludarabin - 221(89%)
TBI (2 GY) - 3 (1%)
TBI (3 GY) + Fludarabin - 1 (0%)
TBI (4 GY) + Fludarabin - 25 (10%)
Patient HO-1 Genotype -
S/S 14 (13%) 26 (10%
S/L 41 (37%) 125 (50%)
L/L 34 (31%) 99 (40%)
Missing 21 (19%) 0 (0%)
P for Hardy-Weinberg equilibrium 0.97 0.34
Karnofsky score
>80 92 (84%) 191 (76%)
80 12 (11%) 27 (11%)
Not available 6 (5%) 32 (12%)
Relapse risk (Kahl Score)
Low risk - 62 (25%)
Standard risk - 140 (56%)
High risk - 48 (19%)
Disease stage (EBMT score)
Early 56 (51%) -
Intermediate 44 (40%) -
Late 10 (9%) -
Overall Survival, median days 1701 2482
Follow-up time, median days (range) 1585 (660–3076) 1119 (272–3229)
DONORS
Donor age, median years (range) 38 (20–59) 42 (19–69)
Sex of donor
M 73 (66%) 144 (58%)
(Continued )
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products from amplification of the (GT)n repeat region in a 3500 Genetic Analyzer (Applied
Biosystems). 1 μL of PCR product was added to 20 μL formamide (95%) and 0.3 μL GeneS-
can™—600 LIZ1 SIZE standard (Applied Biosystems). Fragment length examination was
performed using the GeneMapper software version 4.1 (Applied Biosystems).
Statistical analyses
For our statistical analyses differences in distribution of number of repeats between patients
and donors were tested using a Kolomogorov-Smirnov test. Comparisons of groups of patients
and discrete variables were done using Fisher’s Exact test and comparisons of groups of
patients and continuous variables were performed using the Mann-Whitney test. Overall sur-
vival (OS) and progression-free survival (PFS) was estimated by the Kaplan-Meier method.
Cumulative incidences of relapse/progression, relapse related mortality (RRM), acute and
chronic GVHD were estimated by standard methods for competing risks [10]. A Cox propor-
tional hazard regression model was used for calculating p-values and hazard ratios. Significant
associations between genotype and outcome were further investigated in multivariable Cox
regression models, restricted to include patient age, sex, donor type (related versus unrelated)
and relapse risk (i.e Kahl score for NMA cohort [11] and EBMT for MA cohort [12]) to calcu-
late adjusted hazard ratios and p-values. This was not done on subset analyses on subsets of
data due to the low number of cases. In cases of very few events a permutation test was used
for calculating differences. All tests were two-sided and p-values below 0.05 were considered
significant. IBM SPSS Statistics version 19.0.0 (2010, IBM, Somer, NY, USA) or R Statistical
Software version 3.2.2 (2015, R Foundation, Vienna, Austria) were used for all calculations. R
package “crr” was used for cumulative incidence calculations and function “permlogrank” in
the “clinfunc” package was used for permutation tests.
Table 1. (Continued)
PATIENTS Myeloablative cohort(n = 110) Nonmyeloablative cohort(n = 250)
F 37 (34%) 106 (42%)
Donor HO-1 Genotype
S/S 13 (12%) 35 (14%)
S/L 40 (36%) 114 (46%)
L/L 57 (52%) 101 (40%)
P for Hardy-Weinberg equilibrium 0.37 0.95
PATIENT/DONOR
HLA match
10/10 95 (86%) 231 (92%)
9/10 15 (14%) 19 (8%)
Type of donor
Siblings 34 (31%) 113 (45%)
Other relative 2 (2%) 1(0%)
Unrelated 74 (67%) 136 (55%)
CMV status
Neg/neg 26 (24%) 65 (26%)
Other 81 (74%) 174 (70%)
Missing 3 (3%) 11 (4%)
Values are number of cases with percents in parenthesis, unless otherwise specified. TBI indicates total body irradiation,
doi:10.1371/journal.pone.0168210.t001
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Results and Discussion
First, we used fragment analyses to determine the number of (GT)n repeats among 339 recipi-
ents and 360 donors as well as 74 healthy donors. Alleles were classified as either short
with 26 (GT)n repeats (S) or long with >26 (GT)n repeats (L) [13]. The (GT)n repeat poly-
morphism adhered to the Hardy-Weinberg equilibrium in all 3 cohorts (p = 0.55, p = 0.56,
p = 0.75). The number of (GT)n repeats ranged from 21 to 39 for recipients and 19 to 38 for
donors (S1 Fig). In agreement with previous reports distribution of the alleles was bimodal
with the most common alleles consisting of 23 and 30 (GT)n repeats [13]. The distribution of
alleles was similar between recipients and donors (p = 0.8) and did not differ from that of
healthy donors (p = 0.9 and 0.4, respectively).
Next, we investigated the association between HO-1 genotype in recipients and donors and
clinical outcome after allogeneic MA-HCT. Recipients of grafts from donors with genotype S/
S (HO-1high) had a significantly higher relapse/progression incidence (time to progression) at
3 years (38%, n = 13) than patients receiving grafts from donors with genotypes S/L or L/L
(16%, n = 97) (adjusted hazard ratio (HR) 3.4 (95% confidence interval (CI) 1.3–9.1), p = 0.01,
Fig 1A, Table 2), which translated into lower PFS (S/S, 39%; S/L or L/L, 54%; adjusted HR 2.2
(95% CI 1.0–4.46), p = 0.04) and a trend towards increased RRM (S/S, 38%; S/L or L/L, 16%;
adjusted HR 2.8 (95% CI 1.0–7.9), p = 0.05) at 3 years (Table 2).
No significant difference was observed for OS (S/S, 39%; S/L or L/L, 55%, p = 0.13), and
treatment related mortality (TRM) (S/S, 23%; S/L or L/L, 29%, p = 0.81) at 3 years. We did not
find a significant association to the incidence of acute GVHD (grade II or higher) (S/S, 54%; S/
L or L/L, 54%, p = 0.99) at 1 year or severe acute GVHD (grade III or higher) (S/S, 8%; S/L or
L/L, 18%, p = 0.26) at 1 year (Table 2).
In the NMA setting no association between outcome and genotype where observed, when
statistical analyses were isolated to host genotype only (Table 2). However, HO-1low genotype
(L/L) recipients of HO-1low donors experienced significantly lower RRM (L/L donor into L/L
recipient, 18%, n = 29; L/L donor into S/L or S/S recipient, 31%, n = 25; HR 0.3 (95% CI 0.1–
0.9), p = 0.03, Fig 1B) and increased PFS (L/L donor into L/L recipient, 64%, n = 29; L/L donor
into S/L or S/S recipient, 29%, n = 25; HR 0.4 (95% CI 0.2–0.8), p = 0.008, Fig 1C) at 3 years.
Furthermore, we observed a trend towards higher incidence of grade III-IV acute GVHD (L/L,
Fig 1. Transplantation outcome. (A) Proportion of patients progressing after receiving myeloablative conditioning and grafts from
donors with either S/S (solid line) or S/L or L/L (dotted line) genotype. The p value was adjusted for patient sex, age, relapse risk and
donor type. (B) Incidence of relapse related mortality and (C) progression-free survival according to patient HO1 genotype receiving
nonmyeloablative conditioning and grafts from an HO-1low genotype donor. S/S + S/L (solid line), L/L (dotted line).
doi:10.1371/journal.pone.0168210.g001
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14%, n = 50, S/L or S/S, 2%, n = 51; p = 0.02, permutation test) at 1 year (data not shown). No
other associations between recipient or donor genotype and outcome measures were observed.
We did not observe the same effect of HO-1 genotype in the two cohorts. However, the
results were complementary and in support of previously published animal data indicating
that HO-1 expression favors induction of regulatory T cells (Tregs) and inhibits proliferation
of effector T cells [14], thus mitigating GVT effects. In the MA cohort donorswith an anti-
inflammatory phenotype(HO-1high (S/S) genotype) were associated with increased relapse
related outcome measures, implying that high levels of the anti-inflammatory HO-1 may sup-
press GVT effects. In the NMA cohort transplantation using donors with the pro-inflamma-
tory HO-1low (L/L) genotype in equally phenotypically pro-inflammatory HO-1low (L/L)
recipients was associated with less relapse and superior PFS, implying augmented GVT effects
with less anti-inflammatory drive. The reason for only being able to observe significant associ-
ation between complementary endpoints, and not the same endpoints, across the two cohorts,
may be due to the relatively small cohort sizes and heterogeneity. Due to the same reason the
current observations could not be reproduced in joint analyses of the cohorts.
Only 1 study has previously been published investigating the role of HO-1’s genetic varia-
tion after allogeneic HCT. In a cohort of 92 patients transplanted with in vivo T-cell depleted
grafts from matched related donors MA-HCT, Gerbitz et al. observed that donors with high
HO-1 expression (based on (GT)n repeat genotype) and thus increased anti-inflammatory
drive, were associated with inferior survival due to grade III-IV acute GVHD3 [15]. Gerbitz
et al. hypothesize that expression of HO-1 above a certain threshold may lead to an excessive
Table 2. Uni- and multi-variate analyses of the correlation between donor genotype and transplantation outcome.
Myeloablative conditioning (n = 110)
Unadjusted analysis Adjusted analysis
At 3 yearsa) Pb) HR (95% CI) P
Short GT (SS) (donor) Long GT (SL/LL) (donor)
Overall survival 38.5% (19.3%; 76.5%) 55.3% (46.1%; 66.2%) 0.34 1.8 (0.8; 3.9) 0.13
Progression-free survival 38.5% (19.3%; 76.5%) 54.3% (45.2%; 65.3%) 0.24 2.2 (1.0; 4.6) 0.040
Time to progression 38.5% (5.4%; 60.0%) 16.5% (8.8%; 23.6%) 0.032 3.4 (1.3; 9.1) 0.013
Relapse-related mortality 38.5% (5.4%; 60.0%) 15.6% (8.0%; 22.5%) 0.049 2.8 (1.0; 7.9) 0.048
Treatment-related mortality 23.1% (0%; 42.9%) 29.2% (19.4%; 37.7%) 0.52 1.2 (0.3; 4.0) 0.81
At 1 year
Acute GVHD (grade III+) 7.7% (0%; 21.1%) 17.6% (9.6%; 24.9%) 0.26 - -
Acute GVHD (grade II+) 53.8% (17.0%; 74.3%) 53.9% (43.8%; 62.8%) 0.94 1.0 (0.4; 2.2) 0.99
Nonmyeloablative conditioning (n = 250)
Overall survival 58.7% (43.3%; 79.4%) 63.6% (57.2%; 70.8%) 0.93 1.0 (0.5; 1.7) 0.90
Progression-free survival 44.5% (23.8%; 70.1%) 56.2% (47.5%; 63.1%) 0.49 1.0 (0.6; 1.9) 0.91
Time to progression 33.8% (9.8%; 51.3%) 25.9% (17.2%; 33.7%) 0.52 1.1 (0.6; 2.5) 0.86
Relapse-related mortality 25.7% (3.3%; 43.9%) 21.0% (12.9%; 28.4%) 0.62 0.9 (0.3; 2.6) 0.89
Treatment-related mortality 21.7% (0%; 38.9%) 17.9% (10.4%; 24.8%) 0.92 1.2 (0.4; 3.5) 0.39
At 1 year
Acute GVHD (grade III+) 5.7% (0%; 13.1%) 9.0% (5.0%; 12.8%) 0.61 - -
Acute GVHD (grade II+) 42.9% (23.9%; 57.1%) 30.7% (24.2%; 36.6%) 0.15 1.6 (0.9; 2.9) 0.089
a) For overall survival and progression-free survival, proportion alive Kaplan-Meier estimate. For Time to progression, Relapse-related mortality and
Treatment-related mortality cumulative incidence with competing risks. For acute GVHD cumulative incidence with Kaplan-Meier estimate.
b) Log-rank test when Kaplan-Meier estimate used.
doi:10.1371/journal.pone.0168210.t002
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oxidative burst that induces tissue damage [16]. In contrast, our study implied that high
expression of HO-1 suppresses the GVT effects.
The apparently inconsistent results observed in the current study and often across genetic
association studies may be due to several factors that make direct comparisons difficult. The
generally small cohorts in transplant studies increase the risk of type I errors as the effect of
single genetic variants usually is modest. Furthermore heterogeneity between patient popula-
tions, with differences in treatment regimens, diagnoses, racial admixture and other yet
unknown risk factors, as well as use of different laboratory methods and analyses platforms all
contribute to an unclear picture.
In conclusion, data from the current study suggest that donor HO-1 genotype may be asso-
ciated with the GVT effect in both the MA and NMA setting, hereby implying a role for HO-1
in alloreactivity. To validate the significance of these findings further experimental and clinical
studies are needed to explain the role of HO-1 in alloreactivity and assess the impact on out-
come in a prospective manner with consequences in a clinical setting.
Supporting Information
S1 Fig. Frequency of number of HO-1 (GT)n repeats. We determined the number of (GT)n
repeats among 74 normal donors (normal cohort), 360 donors (donor cohort) and 339 recipi-
ents (recipient cohort). As every individual carries two alleles we analysed 148 normal donor,
720 donor and 678 recipient alleles.
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